<DOC>
	<DOC>NCT02213133</DOC>
	<brief_summary>Open-label, multi-center, single-arm, Phase 2 study of oral selinexor in patients with SCC of the head and neck (HN-SCC; Cohort 1), lung (L-SCC; Cohort 2), or esophagus (E-SCC; Cohort 3) who have relapsed or have metastasis following chemotherapy.</brief_summary>
	<brief_title>Selinexor Treatment of Advanced Relapsed/Refractory Squamous Cell Carcinomas</brief_title>
	<detailed_description>This is a multicenter, open-label, single-arm Phase 2 study of the SINE selinexor given orally to patients diagnosed with advanced SCC of the head and neck, lung, or esophagus who have experienced relapse and/or metastasis following multiple prior chemotherapy treatments (&lt;2 lines of therapy). Patients will receive fixed doses of selinexor tablets twice weekly in 28-day cycles. Patients may continue from one cycle to the next without interruption as along as all criteria are met and no reason for discontinuation occurs.</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Squamous Cell</mesh_term>
	<criteria>18 years of age or older confirmed SCC of the head and neck, lung, or esophagus 1 to 2 prior therapies measurable disease at screening and documented progression within the past 6 weeks patients requiring total parenteral nutrition unstable cardiovascular function substantially impaired gastrointestinal function Symptomatic brain metastases another malignancy within 3 years except adequately treated in situ carcinoma of any type, basal or nonmelanomatous skin cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Squamous</keyword>
	<keyword>SCC</keyword>
	<keyword>Carcinoma</keyword>
	<keyword>KPT-330</keyword>
	<keyword>SINE</keyword>
	<keyword>Selinexor</keyword>
	<keyword>Karyopharm</keyword>
	<keyword>Karyopharm Therapeutics</keyword>
	<keyword>Lung</keyword>
	<keyword>Head</keyword>
	<keyword>Neck</keyword>
	<keyword>Esophageal</keyword>
</DOC>